ABSTRACT Background: Mild vitamin B-12 deficiency is common among older adults, but evidence for setting dietary recommendations is limited because most studies have administered vitamin B-12 via nonoral routes or at doses several hundred times higher than current recommendations. Furthermore, different biomarkers of vitamin B-12 status have not been systematically reviewed. Objective: The aim was to assess the effectiveness of biomarkers of vitamin B-12 status through a systematic review of published randomized controlled trials of oral vitamin B-12 supplementation. Design: Methods included a structured search strategy on Ovid MEDLINE, EMBASE (Ovid), and Cochrane databases; formal inclusion and exclusion criteria; data extraction; validity assessment; and meta-analysis. Results: Eight randomized controlled trials were included, and all studies measured serum and plasma total vitamin B-12, 3 studies measured methylmalonic acid, and 6 studies measured total homocysteine response. All 3 biomarkers were found to be effective measures of altered vitamin B-12 intake in populations with low and borderline baseline vitamin B-12 status (P , 0.00001); however, in the case of total vitamin B-12, substantial heterogeneity that could not be fully explained by subgroup analysis was observed. Insufficient data were available to determine the effectiveness of plasma holotranscobalamin, which was measured in only one randomized controlled trial. Conclusions: The available evidence suggests that plasma and serum concentrations of total vitamin B-12, methylmalonic acid, and total homocysteine are all effective biomarkers of a change in vitamin B-12 intake; however, because the available data were limited, it was not possible to examine fully the factors that could explain the substantial heterogeneity in total vitamin B-12. Future trials should include low-dose vitamin B-12 in adults across the entire age spectrum and measure the holotranscobalamin response to supplementation.
INTRODUCTION
Vitamin B-12 (cobalamin) is found almost exclusively in foods of animal origin in the cofactor forms methyl-, hydroxy-, and deoxyadenosyl-cobalamin (1) . Cyanocobalamin is the form typically used in supplements and fortified foods, although methylcobalamin is used in some non-European countries. All forms of vitamin B-12 are readily converted into the 2 biologically active forms, methyl-and deoxyadenosyl-cobalamin. Vitamin B-12 absorption is dependent on normal functioning of the gastrointestinal tract. Gastric acid and pepsin release vitamin B-12 from proteins in food in order for vitamin B-12 to bind with R proteins (2) . In the duodenum, vitamin B-12 binds to gastric intrinsic factor once it is split from R proteins. The vitamin B-12 intrinsic factor complex then attaches to specific ileal receptors in the terminal ileum (3) , although this pathway has limited capacity because the receptors become saturated at intakes of '3 lg vitamin B-12 from a single meal (4) . A small percentage ('1%) of high-dose vitamin B-12 can be absorbed passive diffusion, independent of intrinsic factor secretion or an intact small intestine (4) .
The 2 biologically active forms of vitamin B-12 are required for the normal functioning of 2 mammalian enzymes. Adenosylcobalamin acts as a cofactor for methylmalonyl CoA mutase, which catalyzes the conversion of methylmalonyl CoA to succinyl CoA. Methylcobalamin acts as a cofactor for methionine synthase (which also requires folate), which is involved in the remethylation of homocysteine to methionine. Thus, in vitamin B-12 deficiency, the respective metabolites methylmalonic acid (MMA) and homocysteine accumulate. Both metabolites are sensitive metabolic markers of tissue deficiency, but whereas elevated MMA is specific to vitamin B-12 deficiency except in renal disease (5) , plasma and serum total homocysteine concentration is influenced by many factors, most notably by variation in folate status (6) , and therefore is a nonspecific marker of low and deficient vitamin B-12 status.
Prevention of low and deficient vitamin B-12 status is of public health importance because it is associated not only with classical deficiency symptoms, such as hematologic abnormalities and irreversible neurological complications, but also potentially with a number of common age-related problems such as cognitive decline (7, 8) , cardiovascular disease (9) , and bone fractures (10, 11) . Although dietary intakes greatly exceed recommendations (the latter ranging from 1 to 2.8 lg/d for adults; 12-17) unless a strict vegan diet is followed (18, 19) , mild vitamin B-12 deficiency (characterized by elevated metabolites and low or low/ normal serum vitamin B-12 concentrations) is common in older people with a reported prevalence of between 10% and 38% (20) (21) (22) (23) , depending on the diagnostic criteria used. The most common cause of this mild deficiency is considered to be foodbound malabsorption caused by atrophic gastritis, an age-related condition resulting in hypochlorhydria. This in turn leads to diminished vitamin B-12 absorption because gastric acid is required for the release of vitamin B-12 from proteins in food (24) . On this basis, the US Institute of Medicine (14) recommends that people aged 50 y consume most of their vitamin B-12 from fortified foods and supplements, but no such recommendation exists elsewhere. Emerging nutrient recommendations should be evidence based, but available evidence with respect to vitamin B-12 is somewhat limited in that most studies have administered vitamin B-12 via nonoral routes or have used doses of vitamin B-12 several hundred times higher than current dietary recommendations.
The primary aim of this study was to carry out a systematic review of randomized controlled trials (RCTs) of oral vitamin B-12 supplements to identify the biomarkers of status that reliably reflect change in vitamin B-12 intake.
METHODS
The methodology was based on the standard methodology developed for this set of reviews (25) and is summarized below, emphasizing any differences from the main methodology.
Inclusion criteria
To be included in this review, a study needed to fulfill all of the following criteria: 1) have an RCT design; 2) be conducted in humans; 3) include a placebo or untreated comparison group; 4) include supplementation with vitamin B-12, cobalamin, cyano-, hydroxy-, or methyl-cobalamin in the form of oral supplements, fortified foods, or through natural food sources; 5) report vitamin B-12 status at baseline and for at least one time point after supplementation; and 6) publish in English or other European language. Studies of factorial design were included if the other treatments (coadministered with vitamin B-12) were shown to have no effect on the biomarker of interest. No minimum duration of supplementation was defined because few studies measured the response of vitamin B-12 biomarkers to supplementation at more than one time point.
Exclusion criteria
Studies were excluded if they met any of the following criteria: 1) used nonoral routes of administration, 2) were conducted in patient groups with preexisting disease on the basis that the biomarker responses might not have been representative of the general population or the disease state might have confounded the outcomes, 3) administered vitamin B-12 in combination with other nutrients or other intervention if the independent effects of vitamin B-12 could not be identified, 4) did not report variance data, and 5) were acute studies (ie, typically one dose with measurement of hourly responses) using radioactive or nonradioactive forms of the vitamin.
Search strategy

Electronic searches
Ovid MEDLINE (www.ovid.com; 1950-week 2, September 2007), EMBASE (Ovid, 1980 (Ovid, -week 38, 2007 , and the Cochrane Library CENTRAL database (www.thecochranelibrary. com; inception to 19 September 2007) were searched for intervention studies of vitamin B-12 using text terms with appropriate truncation and relevant indexing terms. The search was in the form: vitamin B-12 terms AND intervention terms AND human studies. The full Ovid MEDLINE search strategy can be found in Supplemental Table S1 under ''Supplemental data'' in the online issue; the strategies for the other databases were based on this approach.
Reference search
An additional Ovid MEDLINE search was conducted (1950-week 1, September 2007) for reviews of methods of assessing vitamin B-12 status. Eight of these reviews were collected in full text, and the reference lists were checked (26) (27) (28) (29) (30) (31) (32) (33) for studies that appeared to be intervention studies not already assessed for inclusion. In addition, reference lists of the original articles included in this systematic review were also scrutinized for any potential articles not identified by the searches. Unpublished studies or unpublished data from existing studies were not included in this review.
Data collection
Titles and abstracts were screened for inclusion by a single reviewer, and duplicates were removed. Full-text articles were obtained for potentially suitable articles and for those where suitability was unclear from the screening stage. The full text of all articles collected was screened for inclusion using an inclusion/exclusion form by a single reviewer. Data for each included study were extracted onto a Microsoft Access (Microsoft Corp, Redmond, WA) database file by a single reviewer; all extracted data were then checked by a second reviewer. No disagreements occurred between the 2 reviewers. The complete duplication of the screening of articles for inclusion, exclusion, and data extraction, as suggested in the main methodology article (25) in this supplement, was not followed because of time constraints. The data extraction form was tested on a small number of articles by a single reviewer and discussed with the review team before beginning full data extraction.
Data extraction was as discussed in the main methodology article (25) with the following amendments. Corresponding authors of 3 papers were contacted to obtain mean (6SD) values because data in the original articles were presented as in the median and interquartile range (34, 35) or in the median and 5th and 95th percentiles (36) .
Data synthesis
Primary and secondary measures of interest were as stated in the main methodology article (25) , and data synthesis was carried out as described in the main article with the following additional decisions and/or assumptions made for this review: One article reported on 2 separate placebo-controlled trials (36) , which were treated as 2 independent studies in the analysis. In cases in which studies differed in the units used for reporting data, all data (mean 6 SD) were converted to SI units. In cases in which variance data were reported in a form other than 6SD (on the basis that the data were skewed) and in cases in which the SD could not be obtained from the authors, this value was estimated from the reported interquartile range as follows: (top interquartile range) 2 (bottom interquartile range) 3 0.7413. The median values were assumed to be similar to mean values (35) . If postsupplementation data were presented as the percentage change from baseline (37) , these data were converted to absolute change as follows: percentage change from baseline (mean 6 SD) 3 baseline mean value.
For one article, the data presented were assumed to be mean 6 SD (38) . For the presentation of data, responses to intervention were shown in the same plot whether they were presented as change from baseline values (34, 36, 37) or absolute values postintervention (35, (38) (39) (40) . Where studies included 2 vitamin B-12-treated groups and one common control group (34, 37) , the lower dose administered was included only in the secondary analysis (ie, subgroup analysis by dose). However, for the latter analysis, if both vitamin B-12 treatment arms fell within the same range for dose, the groups were combined according to the Cochrane formulas for combining groups (41) . Several studies measured the response at more than one time point, and again the shorter study duration was included only in the secondary analysis (ie, subgroup analysis by duration of treatment; 35, 39) .
RESULTS
The flow diagram outlining the search results for this review is shown in Figure 1 . After the removal of duplicates, 1597 titles and abstracts were screened. Of these, the majority of articles (1572) were excluded primarily because they were review articles or intervention studies where vitamin B-12 was not administered or studies where vitamin B-12 was not administered orally or was administered in combination with other nutrients. Twenty-five articles appeared to be potentially relevant and were collected as full text articles to be assessed for inclusion. Eighteen articles were subsequently excluded for the reasons listed in Figure 1 , which left 8 studies (reported in 7 publications) that fulfilled the inclusion criteria.
Four biomarkers of vitamin B-12 status were identified, but one biomarker, holotranscobalamin (holoTC), was measured in only one study (Figure 1 ), so it was not possible to reliably evaluate its effectiveness. The main focus of this systematic review, therefore, was on the assessment of responses of serum and plasma total vitamin B-12 concentrations, MMA, and total homocysteine as potential biomarkers of vitamin B-12 status, because more than one study reported on each of these outcomes.
Serum and plasma total vitamin B-12 concentrations
Eight RCTs assessed this biomarker, and these studies included 506 participants in studies ranging from 3 (38) to 113 participants per arm (34) . One study was conducted in children and adolescents (34), 3 were conducted in adults (35, 38, 40) , and 4 were in elderly populations (36, 37, 39) . The majority of studies were in populations of both sexes, with one involving male participants only (40) and one in females only (35) . All studies selected participants on the basis of having low vitamin B-12 status at baseline (34, (36) (37) (38) (39) or likely to have a high prevalence of vitamin B-12 deficiency (eg, vegetarians; 35, 40) . The study duration ranged from 4 wk (37) to one school year (ie, three 3-mo periods each with a 1-mo break in between; 34). Five studies administered vitamin B-12 in the form of cyanocobalamin (36, 37, 39, 40) , 2 in the form of methylcobalamin (35, 38) , and one was food based (34) . The dose ranged from physiologic doses present in milk and meat (34) to pharmacologic doses of 1500 lg (38) , and all studies administered the supplements on a daily basis except for 2 studies in which the supplement was administered on a nondaily basis (every alternate day, 35; and 5 times/wk for one school year, 34). Although the biological sample (ie, plasma or serum) varied among studies, immunoassay methods were used in all studies to measure total vitamin B-12 concentrations. For further details, see Table 1 .
All studies were randomized, with 5 providing details on the method of randomization (35, 36, 38, 39) . The reasons for dropouts and exclusions were given in all publications, and there were no dropouts in one study (37) . Compliance was checked in all but one study (38) , and the results of the compliance check were reported in all but one (40) . The dose delivered was checked by measuring levels in the supplements in 4 studies (36, 37, 39) . For further details, see Table 2 .
The forest plot of serum and plasma total B-12 response to vitamin B-12 supplementation is shown in Figure 2 . Concentrations of vitamin B-12 were significantly increased by intervention with vitamin B-12 [8 RCTs; weighted mean difference (WMD): 185 pmol/L; 95% CI: 107, 263 pmol/L; n ¼ 506; P , 0.00001), although heterogeneity was significant (I 2 : 94.6%). Removal of weaker studies [on the basis that n was small and the CI was very large (38) or the supplement was administered on a nondaily basis (34, 35) ] did not change the overall effect (not shown). Subgroup analysis was carried out to try to explain the heterogeneity, and the results are shown in Table 3 . For the majority of secondary analyses, insufficient data were available to answer the questions posed. Adults and elderly people were the only age groups in which sufficient data were available to claim that serum and plasma total vitamin B-12 accurately reflects a change in intake. Cyanocobalamin was the most frequently used form of vitamin B-12 in the supplementation studies, and, as expected, it was found to be a suitable form for improving vitamin B-12 status. The response to methylcobalamin failed to reach statistical significance (P ¼ 0.09), but this finding was based on 2 studies of small sample size. The use of very-low vitamin B-12 doses, in the range 0.75-10 lg, caused a significant increase in vitamin B-12 concentrations (P ¼ 0.0004), and although the greatest overall effect was found at the highest B-12 doses (P , 0.00001), the number of studies using low-dose vitamin B-12 was too small to draw any firm conclusions in relation to dose. The test for heterogeneity remained high for most of the subgroup analysis (I 2 .50%) so population subgrouping does not appear to explain the heterogeneity seen.
Serum and plasma MMA
Three RCTs measured MMA concentrations, and these studies included 186 participants in studies ranging from 19 (37) to 53 participants per arm (39) . All studies were conducted in elderly populations of both sexes, and the study duration was for either 12 (37) or 24 wk (39) . All studies administered vitamin B-12 in the form of cyanocobalamin on a daily basis at pharmacologic doses of 1000 lg. Chromatographic methods [liquid chromatography-mass spectrometry (LC-MS)] were used in all studies. For further details on the characteristics and quality of included studies, see Tables 1 and 2 .
The forest plot of MMA response to vitamin B-12 supplementation is shown in Figure 3 . Concentrations of MMA were significantly lowered by intervention with vitamin B-12 (3 RCTs; WMD: 20.28 lmol/L; 95% CI: 20.35, 20.22 lmol/L; n ¼ 186; P , 0.00001; I 2 : 0%). All 3 studies excluded subjects with impaired renal function. Subgroup analysis was not possible owing to the limited number of studies that measured this marker.
Serum and plasma total homocysteine concentrations
Six RCTs assessed this biomarker, and these studies included 282 participants in studies ranging from 10 participants per arm (37) to 54 participants per arm (39) . Two studies were conducted in adults [one in males only (40) ; one in females only (35) ] and 4 in elderly populations of both sexes (36, 37, 39) . Study duration ranged from 4 (37) to 24 wk (39) . Five studies administered vitamin B-12 in the form of cyanocobalamin (36, 37, 39, 40) and one in the form of methylcobalamin (35) . All studies administered the supplements on a daily basis, which ranged from doses of 10 lg (37) to pharmacologic doses of 1000 lg (36, 39, 40) except for one study in which the supplement was administered every alternate day (35) . Five of the 6 studies used chromatographic methods (HPLC or gas chromatography-mass spectrometry), and all measured total homocysteine in plasma except for one study in which serum was used (37) . For further details on the characteristics and quality of the included studies, see Tables 1 and 2 .
The forest plot of serum and plasma total homocysteine response to vitamin B-12 supplementation is shown in Figure 4 . Concentrations of serum and plasma total homocysteine were significantly lowered by intervention with vitamin B-12 (6 RCTs; WMD: 23.3 lmol/L; 95% CI: 24.5, 22.2 lmol/L; n ¼ 282; P , 0.00001; I 2 : 0%). Results of the subgroup analysis are shown in Table 4 . For the majority of secondary analyses, insufficient data were available to answer the questions posed. The group of older people was the only age group in which sufficient data were available to state that the serum and plasma total homocysteine response accurately reflects a change in vitamin B-12 status. Cyanocobalamin was the most frequently used form of vitamin B-12 in the supplementation studies and, as expected, it was found to be a suitable form for lowering serum and plasma total homocysteine concentrations. There was a trend toward lower total homocysteine concentrations with increasing intakes of vitamin B-12, although this relation reached significance only in the groups receiving the higher doses of vitamin B-12 (.100 lg). However, the number of studies using lowdose vitamin B-12 was too small to draw any firm conclusions.
Plasma holoTC
The effectiveness of holoTC as a biomarker of vitamin B-12 status could not be evaluated as it was measured in only one study. The outcome as reported in the original publication was that holoTC responded significantly to supplementation with high-dose vitamin B-12 (1000 lg/d) for 24 wk in elderly subjects with mild vitamin B-12 deficiency (39).
DISCUSSION
From the potential 25 articles, the current systematic review identified 8 RCTs that reported the response of 4 different biomarkers to supplementation with vitamin B-12. Sufficient data Subjects provided with 500-ml containers of milk along with a 125-ml cup and a diary to record whether the milk was consumed. Subjects recorded how much of the 500 ml was left at the end of each 4-d period.
Compliance assessed by reviewing the diary; 90% consumed .90% of their milk.
Cobalamin-fortified milk contained 7000 lg/L cobalamin (expected value 8000 lg/L) and the placebo milk contained 3.7 lg/L. Samples of the formulations were analyzed for vitamin B-12 content before the study and after storage for 3-mo at room temperature or at 4°C. Concentrations did not fall by .5%. Ubbink et al, 1994 (40) Blinded to participants Intervention, n ¼ 3; control, n ¼ 3. Withdrew or excluded due to lack of compliance.
Blood samples collected at 3 wk and analyzed for B-12 concentrations. Results of check not reported.
None mentioned
were available to show that serum and plasma concentrations of total vitamin B-12, MMA, and total homocysteine respond to intervention with vitamin B-12 in adult populations selected on the basis of having mild vitamin B-12 deficiency or being at risk of deficiency. The evidence, however, was insufficient to establish the effectiveness of holoTC as a biomarker of vitamin B-12 status. In the case of total vitamin B-12 response, substantial heterogeneity was observed among the studies, but the limited number of available studies prevented detailed subgroup analysis being undertaken to fully explain this variability. For the current review, relatively few studies were identified because much of the older literature on vitamin B-12 involved studies of clinical and biochemical responses to nonoral routes of administration, different pharmacologic doses, or different forms of the vitamin in patients with diagnosed vitamin B-12 deficiency. Only in recent years have studies involved healthy populations in light of the evidence that mild vitamin B-12 deficiency has a high prevalence among elderly people (19) and that this condition is associated with a number of chronic diseases such as cognitive decline (7, 8) . Furthermore, studies show that vitamin B-12 becomes the main nutritional determinant of serum and plasma total homocysteine once folate status is optimized (42) (43) (44) (45) and that lowering total homocysteine might be beneficial in the prevention of stroke (46) . Several recent systematic reviews that have addressed important issues such as the role of vitamin B-12 in cognitive function and the effectiveness of different routes of administration (47) (48) (49) have been published, but to our knowledge none have addressed the questions being asked here.
Serum and plasma total vitamin B-12 concentrations increased significantly in response to intervention with vitamin B-12 over supplementation periods of at least 4 wk, although the response varied considerably among studies that measured total vitamin B-12. Likewise, significant decreases in both total homocysteine and MMA concentrations were observed with vitamin B-12 intervention. However, the latter biomarker response was based on 3 studies carried out in the same country with similar population groups, so the conclusions may not necessarily be applicable to other populations. Other inherent weaknesses were that too few trials, mostly of small sample size, were identified, and these varied considerably in terms of the dose and form of supplement administered, study duration, primary outcome, methodologic factors (eg, serum or plasma, fasting or nonfasting (34, 36, 37) or are absolute values postintervention (35, (38) (39) (40) . RCT, randomized controlled trials; WMD, weighted mean difference. samples), and population studied. Few of the studies recruited from the general population but instead focused on subjects recruited from particular locations (eg, a hospital setting or a school), so the findings may not be applicable to all subgroups. Study populations varied from apparently healthy subjects with mild vitamin B-12 deficiency or at risk of deficiency to subjects attending outpatient clinics, which could therefore confound the study outcomes. Furthermore, several studies permitted the inclusion of participants taking vitamin B-12 supplements at the time of recruitment as long as the intake was at low doses. Although all trials were randomized, few provided details on the method of randomization used. Probably of greatest importance is the fact that only 1 of the 8 trials administered vitamin B-12 with food (40) . This might be a major limitation in the extent of the response observed because the presence of food is recognized as being necessary to stimulate the normal vitamin B-12 absorptive mechanisms (4) . Subgroup analysis was undertaken to explore the factors that might have contributed to the variability in total vitamin B-12 response among the studies, but the above limitations (particularly the small number of published RCTs) mean that our conclusions should be interpreted with caution. Two potential factors that could determine response to any nutrient supplementation are the age and sex of the study population. In the case of vitamin B-12, age is considered to be the far more critical factor and, in fact, most RCTs included in this review involved older adults selected on the basis of having mild vitamin B-12 deficiency, presumably (although not explicitly) a result of food-bound vitamin B-12 malabsorption. Furthermore, although we did not specifically exclude studies involving food- (36, 37) or are absolute values postintervention (35, 39, 40) . RCT, randomized controlled trials; WMD, weighted mean difference. 2 To claim whether a biomarker was useful, the following terms indicate the conditions needed to be met: ''yes,'' forest plot showed a significant effect (P , 0.05) based on 3 studies and 50 participants between the intervention and control arms; ''unclear but likely to be useful,'' forest plot showed a significant effect (P , 0.05), but the result was based on 2 studies; ''unclear,'' insufficient data were available. based interventions, only one such study (of children) was included (34) , and its removal from subgroup analyses for separate reasons did not change the outcomes. Thus our findings generally support the widely held view that the provision of free vitamin B-12 (even at very low doses) should be effective in those with food-bound malabsorption (14) .
Differences in the dose administered appeared to account for the majority of variability among the studies that measured total vitamin B-12 response. As expected, pharmacologic doses of vitamin B-12 (.1000 lg/d) caused the greatest increase in serum and plasma total vitamin B-12 concentration although lowdose vitamin B-12 (,10 lg/d), provided as a supplement or through natural food sources, resulted in a small but significant increase in total vitamin B-12 values. Recent evidence from an observational study shows that a total vitamin B-12 intake (from diet and supplements) of 6 lg/d was sufficient to normalize plasma total vitamin B-12, MMA, holoTC, and total homocysteine in healthy postmenopausal women (16) . Evidence from trials with low-dose vitamin B-12, however, is conflicting. Some report no effect on MMA or total homocysteine (50) whereas others report a significant lowering of these metabolites (51, 52) . Because these latter studies were of short duration and were not placebo controlled, clearly further studies with low-dose vitamin B-12, including doses equivalent to normal dietary intakes from food and of varying duration, are warranted.
Only 2 of the 6 studies in this review that measured total homocysteine response included this biomarker as a primary outcome (35, 40) . Homocysteine is not a specific marker of vitamin B-12 status because it is influenced by many factors such as age, sex, and B-vitamin status, in particular, folate (53) . Although none of the studies pretreated with folic acid or randomized by folate status before vitamin B-12 supplementation, a few included a parallel group treated with folic acid alone or in combination with vitamin B-12 and reported a greater reduction in total homocysteine concentrations compared with vitamin B-12 alone (39, 40) . Thus the homocysteine-lowering response observed in the studies included in this review might have been confounded by a number of factors, in particular, differences in folate status.
Insufficient data were available to draw any conclusions about the effectiveness of serum holoTC as a biomarker of vitamin B-12 status in this review, but the limited evidence to date suggests that this biomarker (which measures the small fraction of total circulating vitamin B-12 that is available for metabolic activity; 54, 55) might offer a more sensitive and early indicator of altered vitamin B-12 status than serum and plasma total vitamin B-12, which is the most widely used marker to measure status.
The process of study selection highlighted that the quality of published data is often poor. It was noted that studies are often vague about the measure of variance used to present data or fail to include this. The reporting of the number of subjects who start and who complete intervention and are included in the statistical analysis is often unclear. Figures, although visually effective, often lack important information, or the data are difficult to extract from the figure. Many articles state the assay used to analyze samples but provide no further details or reference to the laboratory methodology. These issues should be considered when publishing study results to ensure that future systematic reviews do not exclude important and well-designed studies that lack the necessary details at publication. This review highlights a number of gaps in the field of vitamin B-12 research. Well-designed RCTs of sufficient size and with varying doses (including doses equivalent to dietary intakes) and duration of supplementation are required in adults across the entire age spectrum. Such studies will establish the optimal dose and duration of treatment with vitamin B-12 that are necessary to normalize status in adults and will be of relevance to those tasked with revising dietary recommendations. Furthermore, studies should include holoTC as an outcome measure to determine the efficacy of this biomarker and make use of the new automated immunoassays available for measuring biological samples. (Other articles in this supplement to the Journal include references 25 and 56-62.)
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